Fructooligosaccharide Supplementation Improves Glucose Homeostasis in Human-Relevant hyperglycemic Diet-Induced Obese Mice
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Fructooligosaccharides (FOS) are prebiotic fibers that influence gut microbiota and host metabolic function. In a diet-induced obesity (DIO) mouse study, FOS supplementation was compared with PBS-treated obese controls. Blood glucose was markedly lower at Day 42 (221.9 ± 7.8 vs 138.3 ± 9.0 mg/dL), and remained lower at Day 56. FOS reduced body-weight gain from 8.4 ± 0.9 g in PBS controls to 2.6 ± 0.2 g, corresponding to an approximate 69.5% reduction in gain over Days 1-70. Cumulative feed consumption was not significantly different between PBS and FOS cages, suggesting that the observed metabolic effects were not explained simply by reduced food intake. These data support our thesis that FOS works as an active metabolic ingredient acting through the gut-liver-metabolic axis. Thus, in the present study, dietary FOS supplementation produced marked improvements in glucose homeostasis in a severe DIO model characterized by diabetic-range hyperglycemia that more closely resembles poorly controlled human type 2 diabetes.
HIGHLIGHTS
-
Fructooligosaccharide (FOS) normalized glucose levels in a severe DIO model that mimics poorly controlled human type 2 diabetes.
-
Day-42 blood glucose was reduced by ∼37.7% in FOS-treated DIO mice.
-
FOS reduced body-weight gain by ∼69.5% versus controls over 70 days.
-
Metabolic benefits occurred without a statistically significant reduction in feed intake.
-
Findings support a gut–liver–metabolic mechanism rather than simple caloric restriction.
-
Data position FOS as an active metabolic ingredient with potential utility in diabetes and metabolic health.
